Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?
2026-07-14 10:10
•Adria Cimino •The Motley Fool
••• •• Axe Capital view
Eli Lilly’s Slow Start in Oral Weight Loss Drugs Raises Eyebrows
Foundayo’s sluggish early sales trail Novo Nordisk’s Wegovy, but the bigger story is market share and pipeline depth.
Eli Lilly’s latest oral weight loss drug, Foundayo, hasn’t caught fire in its first five weeks, far behind Novo Nordisk’s oral Wegovy. While this might spook some investors, the lull might be more about timing and coverage issues than product failure. Lilly still commands a hefty 60% share in the U.S. obesity drug market, thanks largely to its injectable GLP-1 offerings. Weight loss drugs are booming, driven by rising obesity and patient preference for oral treatments. Novo’s strong prescription numbers show Lilly’s foot is on the gas pedal, but Lilly’s deeper pipeline and scale can’t be ignored. For South African investors, the local pharma sector isn’t directly exposed here, but the USD/ZAR exchange rate is relevant as currency fluctuations impact costs of imports and multinational earnings. A weaker rand could pressure margins, but would also make exports more competitive. I’d watch Lilly but avoid chasing Foundayo’s early trends. this is just my opinion and not financial advice
Hold Eli Lilly cautiously; wait for clearer evidence that Foundayo gains traction before adding to positions. Consider monitoring USD/ZAR as a proxy for currency risk in pharma exports.
- LLY
- USD/ZAR
- Foundayo’s slow adoption continues and erodes Lilly’s market share
- Rand weakness impacting multinational earnings and cost structures
6/10
Eli Lilly's new oral weight loss drug Foundayo is showing concerning early signs with flat prescription growth over five weeks post-launch, significantly trailing Novo Nordisk's oral Wegovy. However, analysts note that Foundayo's slower start may be temporary due to later pharmacy coverage and being a new drug formulation, while Lilly maintains a strong 60% U.S. market share and deep pipeline in the rapidly growing weight loss drug market.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Adria Cimino
Categories: Forex, Healthcare, Equities
Tickers: LLY, NVO
Sentiment: Positive - While Foundayo's flat prescription growth is concerning, Lilly maintains market leadership with 60% U.S. share and a strong pipeline. The article suggests the slow oral launch may be temporary due to coverage delays and being a new formulation, not indicative of fundamental weakness. Novo's oral Wegovy is showing significantly stronger early adoption with over 105,000 prescriptions at 13 weeks post-launch compared to Foundayo's 19,550, demonstrating superior market traction in the oral weight loss segment.
Keywords: weight loss drugs, GLP-1 drugs, Foundayo, oral medications, prescription growth, market leadership, pharmaceutical competition
Insights:
- LLY: Neutral: While Foundayo's flat prescription growth is concerning, Lilly maintains market leadership with 60% U.S. share and a strong pipeline. The article suggests the slow oral launch may be temporary due to coverage delays and being a new formulation, not indicative of fundamental weakness.
- NVO: Positive: Novo's oral Wegovy is showing significantly stronger early adoption with over 105,000 prescriptions at 13 weeks post-launch compared to Foundayo's 19,550, demonstrating superior market traction in the oral weight loss segment.